Key Takeaways
JPMorgan Chase & Co. boosted its price target for MicroPort MedBot-B (02252.HK) to HKD 42 from HKD 41, citing a strategic shift at the company from "commercialization validation" to a clear focus on "earnings release." The bank maintained its "Overweight" rating on the stock.
The bullish revision comes after the surgical robot maker issued strong guidance for the year, expecting revenue of approximately RMB 1.1 billion. "The guidance marks a clear shift," JPMorgan's analysts said in a research report, highlighting management's new targets for profitability and positive free cash flow which signal an entry into an operating leverage phase.
MicroPort MedBot has installed 23 of its Toumai surgical robots as of early April and holds a backlog of 86 orders. Management is guiding for at least 200 total installations for the full year, noting that delivery bottlenecks experienced in the second half of 2025 have been resolved. The bank identified overseas markets, including Europe, Asia (excluding China), and Latin America, as the core growth engine.
JPMorgan raised its gross margin assumptions for the company by five to six percentage points for 2026 through 2028 and named MicroPort MedBot its top pick in the MedTech sector. The bank’s 2026 revenue forecast of RMB 1.4 billion remains above market consensus. In the same report, the bank reiterated an "Overweight" rating on parent company MicroPort Scientific (00853.HK) but trimmed its target price to HKD 18 from HKD 18.2.
The upgraded target suggests management's confidence in accelerating sales and achieving profitability is credible. Investors will watch for the company's execution on its ambitious 200-unit installation target for the year to confirm the growth trajectory.
This article is for informational purposes only and does not constitute investment advice.
